

Chemicals/Finland, November 22, 2019 Company update

Turnaround progressing well

Exel Composites updated its guidance for FY '19. The update wasn't big news as progress has been good this year. We make small revisions to our profitability estimates, and our new TP is EUR 6.00 (5.50), rating now HOLD (BUY).

EBIT has improved considerably this year

Exel Composites updated its FY '19 guidance. The company had previously guided improving revenue and adjusted EBIT compared to previous year. The updated outlook guides increase in revenue (as before) and significant increase in adjusted EBIT. The positive guidance update didn't come as a major surprise as Exel had already accumulated EUR 5.9m in adjusted EBIT during the first nine months of the year, compared to the EUR 5.0m for FY '18. Exel says there have been no material changes to order activity since the release of Q3 figures. We thus continue to expect further extension to the recent segmental performance trends. We see Construction & Infrastructure growing at a 10% annual rate, whereas we expect more muted 3-5% CAGR development for Industrial Applications and Other Applications.

Good volumes and cost savings program have helped EBIT

We see no reason to make changes to our top line estimates, i.e. we still estimate Exel's revenue to grow at a 7% annual rate during the next few years. Exel expects to fully realize the annual savings target of EUR 3m during 2020. Although visibility is limited, we make small upward revisions to our profitability estimates. We now expect EUR 2.3m in Q4 EBIT (previously EUR 2.1m). For FY '20 we now estimate the figure at EUR 9.2m (previously EUR 8.6m). In other words, we see Exel achieving operating margins at above 8% going forward. Such a level still falls short of the company's long-term target (Exel targets long-term adjusted operating margin at above 10%).

Long-term upside remains due to operating leverage

In our view more positive development can be expected; higher revenues will further lift operating margin. There's still long-term upside potential in Exel, however we see certain caution is in order due to limited visibility. We regard EV/EBITDA and EV/EBIT multiples of some 7-8x and 11-12x for this year and next as reasonable (roughly 30% below peer medians). We update our TP to EUR 6.00 (5.50); our new rating is therefore HOLD (BUY).



■ BUY □ HOLD ■ SELL

KEY FIGU	RES										
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR	
2017	86.3	6.1	7.1%	-0.5	0.35	18.6	1.0	14.2	-0.6	0.30	
2018	96.6	2.2	2.3%	-11.4	0.03	119.0	0.8	34.5	-24.0	0.18	
2019E	105.0	6.3	6.0%	2.1	0.34	17.1	0.9	15.4	3.0	0.20	
2020E	112.4	9.2	8.2%	4.6	0.52	11.2	0.8	10.3	6.7	0.20	
2021E	120.2	10.0	8.3%	4.9	0.57	10.2	0.8	9.2	7.1	0.25	
Market cap	, EURm		69 G	earing 2019E,	0/0	102.7 CAGR EPS 2018-21, %					
Net debt 2	019E, EURm		28 P	rice/book 2019	E		2.5 CAGR	sales 2018-	21, %	7.6	
Enterprise	value, EURm	EURm 97 Dividend yield 2019E, %						15.0			
Total assets	s 2019E, EURn	n	83 Ta	ax rate 2019E,	0/0			10.7			
Goodwill 2	019E, EURm		13 E	quity ratio 201	9E, %		33.2 PEG, P	P/E 19/CAGR		0.8	



Chemicals/Finland, November 22, 2019 Company update

Estimates summary

Exel Composites	2017	Q1/'18	02/'18	Q3/'18	Q4/'18	2018	Q1/'19	Q2/'19	Q3/'19	Q4/'19E	2019E	2020E	2021E
Industrial Applications	48.2	11.3	11.2	8.8	8.6	39.9	9.3	9.5	7.9	8.0	34.7	36.4	38.3
Construction & Infrastructure	21.3	5.6	8.6	9.8	12.9	36.9	11.3	10.9	10.9	14.3	47.4	52.2	57.5
Other Applications	16.7	4.7	5.4	4.6	5.2	19.9	6.5	6.0	4.8	5.5	22.8	23.7	24.4
Revenue	86.3	21.5	25.2	23.2	26.7	96.6	27.1	26.5	23.6	27.8	105.0	112.4	120.2
change, %	18 %	6 %	9 %	13 %	19 %	12 %	26 %	5 %	2 %	4 %	9 %	7 %	7 %
Adjusted EBIT	6.3	1.8	2.0	0.5	0.8	5.0	2.0	2.2	1.7	2.3	8.1	9.2	10.0
EBIT	6.1	1.6	1.3	0.5	-1.2	2.2	0.4	2.1	1.5				
-margin, %	7.3 %	8.4 %	7.8 %	2.1 %	2.9 %	5.2 %	7.2 %	8.5 %	7.0 %	8.1 %	7.7 %	8.2 %	8.3 %
-margin (reported), %	7.0 %	7.4 %	5.2 %	2.0 %	-4.3 %	2.3 %	1.5 %	8.1 %	6.2 %		6.0 %		

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	19	20	21	19	20	21	19	20	21
Gurit Holding	585	10.3x	9.7x	9.4x	14.0x	12.4x	12.1x	9.1 %	10.0 %	10.1 %
Hexagon Composites	605	23.4x	17.2x	13.1x	65.5x	31.5x	20.4x	3.4 %	5.8 %	7.7 %
Hexcel	5951	13.5x	12.6x	12.0x	18.1x	16.8x	16.0x	18.2 %	18.6 %	18.7 %
PolyOne	2196	11.3x	11.6x	11.2x	16.6x	15.7x	14.4x	7.3 %	8.2 %	8.6 %
SGL Carbon	527	8.4x	6.9x	6.4x	25.6x	19.3x	14.5x	2.9 %	3.8 %	4.8 %
TPI Composites	518	9.2x	6.3x	4.5x	33.5x	12.8x	7.0x	1.6 %	3.7 %	5.9 %
Peer Group Average	1730	12.7x	10.7x	9.4x	28.9x	18.1x	14.1x	7.1 %	8.3 %	9.3 %
Peer Group Median	595	10.8x	10.6x	10.3x	21.9x	16.2x	14.4x	5.4 %	7.0 %	8.1 %
Exel Composites (Evli est.)	69	8.1x	6.4x	5.9 x	15.4x	10.3x	9.2x	6.0 %	8.2 %	8.3 %
Exel Composites prem./disc. to peer me	edian	-25 %	-40 %	-43 %	-30 %	-37 %	-36 %	12 %	18 %	2 %

Source FactSet, Evli Research

Chemicals/Finland, November 22, 2019 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	5.76 PV of Free Cash Flow	53 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	6.78 PV of Horizon value	59 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	17.8 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	7.5 Marketable securities	5 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	6.2 Debt - dividend	-35 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	52.7 Value of stock	81 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2018	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	Horizon
Net sales	97	105	112	120	127	135	142	146	150	153	155	157
Sales growth, %	11.9	8.7	7.0	7.0	6.0	6.0	5.0	3.0	2.5	2.0	1.5	1.5
Operating income (EBIT)	2	6	9	10	11	11	11	11	11	11	12	12
Operating income margin, %	2.3	6.0	8.2	8.3	8.5	8.0	8.0	7.5	7.5	7.5	7.5	7.5
+ Depreciation+amort.	6	6	6	6	6	6	6	6	6	5	5	
EBITDA	8	12	15	16	17	17	17	17	17	16	17	
- Paid taxes	-2	-2	-3	-3	-3	-3	-3	-3	-3	-3	-3	
- Change in NWC	-8	-1	-1	-1	-1	-1	-1	-1	-1	-1	0	
NWC / Sales, %	<i>16.1</i>	16.2	16.3	16.4	16.5	16.5	16.5	16.6	16.6	16.6	16.6	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-9	-4	-4	-4	-4	-4	-5	-5	-5	-5	-5	
opCAPEX / Sales, %	9.7	5.9	5.4	5.2	4.9	4.8	4.6	4.5	4.4	3.6	3.5	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	-11	4	7	7	8	8	8	9	9	8	9	123
= Discounted FCFF		4	6	6	6	6	6	5	5	4	4	59
= DFCF min WACC		4	6	6	6	6	6	5	5	4	4	66
= DFCF max WACC		4	6	6	6	5	5	5	5	4	4	52

Chemicals/Finland, November 22, 2019 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2018Q1	2018Q2	2018Q3	2018Q4	2018	2019Q1	2019Q2	2019Q3	2019Q4E	2019E	2020E	2021E
Net sales	21.5	25.3	23.1	26.7	96.6	27.1	26.5	23.6	27.8	105.0	112.4	120.2
EBITDA	2.5	23.3	1.8	1.2	7.7	1.8	3.4	2.9	3.9	12.0	15.0	15.8
EBITDA margin (%)	11.6	2.2 8.7	7.8	4.5	8.0	6.6	13.0	12.1	14.0	11.4	13.3	13.1
EBIT	1.6	1.3	0.5	-1.2	2.2	0.4	2.1	1.5	2.3	6.3	9.2	10.0
EBIT margin (%)	7.4	5.1	2.2	-4.5	2.2	1.5	7.9	6.4	8.3	6.0	8.2	8.3
Net financial items	-0.4	0.2	0.0	-0.3	-0.5	-0.2	-0.2	-0.2	-0.2	-0.8	-0.8	-0.7
Pre-tax profit	1.2	1.5	0.5	-1.5	1.7	0.2	1.9	1.3	2.1	5.5	8.4	9.3
Tax	-0.3	-0.5	-0.4	-0.1	-1.3	-0.6	-0.3	-0.3	-0.3	-1.5	-2.3	-2.5
Tax rate (%)	25.0	33.3	80.0	-6.7	76.5	300.0	-0.3 15.8	23.1	14.3	27.3	-2.3 27.3	27.3
Net profit	0.9	1.0	0.1	-1.6	0.4	-0.4	1.6	1.0	1.8	4.0	6.1	6.7
EPS	0.9	0.08	0.01	-0.13	0.03	-0.4	0.13	0.08	0.15	0.34	0.52	0.57
EPS adjusted (diluted no. of shares)	0.08	0.08	0.01	-0.13	0.03	-0.03	0.13	0.08	0.15	0.34	0.52	0.57
Dividend per share	0.00	0.00	0.00	0.00	0.03	0.00	0.13	0.00	0.00	0.20	0.32	0.37
	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.00	0.00	0.20	0.20	0.25
SALES, EURm	04.5	05.0	00.1	007	00.0	07.1	00.5	00.0	07.0	105.0	110.1	100.0
Exel Composites	21.5	25.3	23.1	26.7	96.6	27.1	26.5	23.6	27.8	105.0	112.4	120.2
Total	21.5	25.3	23.1	26.7	96.6	27.1	26.5	23.6	27.8	105.0	112.4	120.2
SALES GROWTH, Y/Y %												
Exel Composites	5.9	9.5	13.2	18.7	11.9	26.0	4.7	2.2	4.1	8.7	7.0	7.0
Total	5.9	9.5	13.2	18.7	11.9	26.0	4.7	2.2	4.1	8.7	7.0	7.0
EBIT, EURm												
Exel Composites	1.6	1.3	0.5	-1.2	2.2	0.4	2.1	1.5	2.3	6.3	9.2	10.0
Total	1.6	1.3	0.5	-1.2	2.2	0.4	2.1	1.5	2.3	6.3	9.2	10.0
EBIT margin, %										·	Ÿ	
Exel Composites	7.4	5.1	2.2	-4.5	2.3	1.5	7.9	6.4	8.3	6.0	8.2	8.3
Total	7.4	5.1	2.2	-4.5	2.3	1.5	7.9	6.4	8.3	6.0	8.2	8.3

Chemicals/Finland, November 22, 2019 Company update

INCOME STATEMENT, EURm	2014	2015	2016	2017	2018	2019E	2020E	2021E
Sales	79.3	80.2	73.1	86.3	96.6	105.0	112.4	120.2
Sales growth (%)	14.4	1. 1	-8.9	18.1	11.9	8.7	7.0	7.0
EBITDA	12.5	7.3	3.8	9.3	7.7	12.0	15.0	15.8
EBITDA margin (%)	15.8	9.1	5.2	10.8	8.0	11.4	13.3	13.1
Depreciation	-3.1	-2.9	-3.2	-3.2	-5.5	-5.7	-5.8	-5.8
EBITA	9.4	4.4	0.6	6.1	2.2	6.3	9.2	10.0
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	9.4	4.4	0.6	6.1	2.2	6.3	9.2	10.0
EBIT margin (%)	11.9	5.5	0.8	7.1	2.3	6.0	8.2	8.3
Reported EBIT	8.9	4.0	-1.2	6.1	2.2	6.3	9.2	10.0
EBIT margin (reported) (%)	11.2	5.0	-1.6	7.1	2.3	6.0	8.2	8.3
Net financials	-0.4	-0.2	-0.1	-0.7	-0.5	-0.8	-0.8	-0.7
Pre-tax profit	9.0	4.2	0.5	5.4	1.7	5.5	8.4	9.3
Taxes	-2.8	-1.4	-0.2	-1.2	-1.3	-1.5	-2.3	-2.5
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	5.7	2.4	-1.4	4.2	0.4	4.0	6.1	6.7
Cash NRIs	-0.5	-0.4	-1.8	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	13	15	17	16	21	21	21	21
Goodwill	10	10	10	13	13	13	13	13
Right of use assets	0	0	0	0	5	5	6	6
Inventory	10	10	9	12	15	17	18	19
Receivables	11	12	10	15	20	22	23	25
Liquid funds	8	8	7	8	5	5	6	6
Total assets	52	54	54	64	79	83	87	90
Liabilities								
Shareholder's equity	30	31	27	29	26	28	31	36
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	0	0	0	3	5	6	6
Deferred taxes	1	1	1	0	0	0	0	0
Interest bearing debt	6	8	14	16	30	28	26	24
Non-interest bearing current liabilities	16	14	12	18	18	20	22	23
Other interest-free debt	0	1	1	0	2	2	2	2
Total liabilities	52	54	54	64	79	83	87	90
CASH FLOW, EURm								
+ EBITDA	13	7	4	9	8	12	15	16
- Net financial items	0	0	0	-1	0	-1	-1	-1
- Taxes	-2	-1	0	-2	-2	-1	-2	-3
- Increase in Net Working Capital	0	-3	1	-1	-8	-1	-1	-1
+/- Other	0	0	-2	0	0	0	0	0
= Cash flow from operations	10	3	3	6	-2	8	11	11
- Capex	-5	-4	-6	-6	-9	-6	-6	-6
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0 -2	0	0	0	0 2	0 5	0
= Free cash flow	5		-3	0	-11			5
+/- New issues/buybacks	1	1	0	-1 1	0	0	0	0
- Paid dividend	0	-2	-3	-1 2	-4 12	-2 0	-2	-2
+/- Other	-7 1	3 0	5	3 0	12 -3	0	-2 0	- <u>2</u> 0
Change in cash	-1	U	-1	U	-3	U	U	U

Chemicals/Finland, November 22, 2019 Company update

KEY FIGURES	2015	2016	2017	2018	2019E	2020E	2021E
M-cap	77	60	78	48	69	69	69
Net debt (excl. convertibles)	1	6	9	28	28	26	24
Enterprise value	78	66	87	76	97	95	92
Sales	80	73	86	97	105	112	120
EBITDA	7	4	9	8	12	15	16
EBIT	4	1	6	2	6	9	10
Pre-tax	4	1	5	2	6	8	9
Earnings	3	0	4	0	4	6	7
Equity book value (excl. minorities)	31	27	29	26	28	31	36
Valuation multiples							
EV/sales	1.0	0.9	1.0	0.8	0.9	0.8	0.8
EV/EBITDA	10.7	17.3	9.3	9.9	8.1	6.3	5.9
EV/EBITA	17.7	109.9	14.2	34.5	15.4	10.3	9.2
EV/EBIT	17.7	109.9	14.2	34.5	15.4	10.3	9.2
EV/OCF	28.7	24.3	15.8	-36.8	11.8	8.9	8.3
EV/FCFF	-50.9	-22.6	-67,116.9	-6.9	21.8	13.8	12.6
P/FCFE	-44.1	-20.1	-166.0	-4.2	33.0	15.0	14.0
P/E	27.3			119.0			10.2
r/c P/B	27.3	164.3 2.2	18.6		17.1 2.5	11.2	
•			2.7	1.8		2.2	1.9
Target EV/EBITDA	0.0	0.0	0.0	0.0	8.3	6.5	6.0
Target EV/EBIT	0.0	0.0	0.0	0.0	15.8	10.6	9.5
Target EV/FCF	0.0	0.0	0.0	0.0	48.1	21.3	19.4
Target P/B	0.0	0.0	0.0	0.0	2.6	2.3	2.0
Target P/E	0.0	0.0	0.0	0.0	17.8	11.6	10.6
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.24	0.03	0.35	0.03	0.34	0.52	0.57
Operating cash flow per share	0.23	0.23	0.46	-0.17	0.69	0.89	0.94
Free cash flow per share	-0.15	-0.25	-0.04	-0.96	0.17	0.38	0.41
Book value per share	2.57	2.24	2.42	2.16	2.32	2.64	3.00
Dividend per share	0.22	0.10	0.30	0.18	0.20	0.20	0.25
Dividend payout ratio, %	92.5	327.2	85.0	535.4	59.5	38.8	44.1
Dividend yield, %	3.4	2.0	4.6	4.5	3.5	3.5	4.3
FCF yield, %	-2.3	-5.0	-0.6	-24.0	3.0	6.7	7.1
Efficiency measures							
ROE							20.1
	9.4	1.3	15.2	1.5	15.0	20.8	20.1
ROCE	9.4 12.1	1.3 1.8	15.2 14.6	1.5 4.5	15.0 10.7	20.8 15.0	15.7
ROCE Financial ratios							
Financial ratios	12.1	1.8	14.6	4.5	10.7	15.0	15.7
Financial ratios Inventories as % of sales	12.1	1.8	14.6	4.5	10.7	15.0	15.7
Financial ratios Inventories as % of sales Receivables as % of sales	12.1 12.1 14.3	1.8 12.0 14.0	14.6 13.5 17.1	4.5 15.7 20.8	10.7 15.7 20.8	15.0 15.7 20.8	15.7 20.8
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	12.1 12.1 14.3 17.1	1.8 12.0 14.0 17.0	14.6 13.5 17.1 21.4	4.5 15.7 20.8 19.2	10.7 15.7 20.8 19.2	15.7 20.8 19.2	15.7 15.7 20.8 19.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, %	12.1 12.1 14.3 17.1 9.3	1.8 12.0 14.0 17.0 9.0	13.5 17.1 21.4 9.3	4.5 15.7 20.8 19.2 16.1	15.7 20.8 19.2 16.2	15.7 20.8 19.2 16.3	15.7 15.7 20.8 19.2 16.4
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	12.1 14.3 17.1 9.3 5.6 5.6	1.8 12.0 14.0 17.0 9.0 7.8 7.8	13.5 17.1 21.4 9.3 6.9 6.9	15.7 20.8 19.2 16.1 9.7 9.7	10.7 15.7 20.8 19.2 16.2 5.9	15.0 15.7 20.8 19.2 16.3 5.4 5.4	15.7 15.7 20.8 19.2 16.4 5.2 5.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	12.1 12.1 14.3 17.1 9.3 5.6	1.8 12.0 14.0 17.0 9.0 7.8	13.5 17.1 21.4 9.3 6.9	15.7 20.8 19.2 16.1 9.7	10.7 15.7 20.8 19.2 16.2 5.9 5.9	15.0 15.7 20.8 19.2 16.3 5.4 5.4 0.5	15.7 20.8 19.2 16.4 5.2
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	12.1 14.3 17.1 9.3 5.6 5.6 -0.2	1.8 12.0 14.0 17.0 9.0 7.8 7.8 -0.8 1.6	13.5 17.1 21.4 9.3 6.9 6.9 0.0 0.9	4.5 15.7 20.8 19.2 16.1 9.7 9.7 -1.4 3.7	10.7 15.7 20.8 19.2 16.2 5.9 5.9 0.4 2.4	15.0 15.7 20.8 19.2 16.3 5.4 5.4 0.5	15.7 20.8 19.2 16.4 5.2 5.2 0.5
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	12.1 14.3 17.1 9.3 5.6 5.6 -0.2 0.1	1.8 12.0 14.0 17.0 9.0 7.8 7.8 -0.8	13.5 17.1 21.4 9.3 6.9 6.9 0.0	4.5 15.7 20.8 19.2 16.1 9.7 9.7 -1.4	10.7 15.7 20.8 19.2 16.2 5.9 5.9 0.4	15.0 15.7 20.8 19.2 16.3 5.4 5.4 0.5	15.7 20.8 19.2 16.4 5.2 5.2 0.5

Chemicals/Finland, November 22, 2019 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE:

OWNERSHIP STRUCTURE	SHARES	EURm	%
Nordea Bank ABP (Nom. reg.)	2,145,822	12.360	18.0%
Skandinaviska Enskilda Banken AB (Nom. reg.)	778,610	4.485	6.5%
Sijoitusrahasto Taaleritehdas Mikro Markka	650,000	3.744	5.5%
OP-Finland Small Firms Fund	598,259	3.446	5.0%
Phoebus Fund	290,000	1.670	2.4%
Säästöpankki Pienyhtiöt	288,710	1.663	2.4%
Danske Invest Finnish Institutional Equity Fund	265,000	1.526	2.2%
Ilmarinen Mutual Pension Insurance Company	242,733	1.398	2.0%
Nelimarkka Heikki Antero	230,495	1.328	1.9%
Veritas Pension Insurance Company Ltd.	226,163	1.303	1.9%
Ten largest	5,715,792	32.923	48%
Residual	6,181,051	35.603	52%
Total	11,896,843	68.526	100%

EARNINGS CALENDAR	
February 18, 2020	FY 2019 Results
May 06, 2020	Q1 report
July 21, 2020	Q2 report
October 30, 2020	Q3 report
OTHER EVENTS	

COMPANY MISCELLANEOUS

CEO: Riku Kytömäki CFO: Mikko Kettunen IR: Noora Koikkalainen Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, November 22, 2019 Company update

DEFINITIONS

P/E	EPS
	LI J
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares
Total assets	Gearing
Balance sheet total	<u>Net debt</u> Equity
Div yield, %	Debt/Equity, %
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets - interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, November 22, 2019 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 timer per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 1st of February 2019. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [22.11.2019, 9:05]. This report has been published on [22.11.2019, 9:20].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, November 22, 2019 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, November 22, 2019 Company update

Contact information SALES, TRADING AND RESEARCH

Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Roankanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120	Joachim Dannberg Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9130
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001